Browse Studies — Arctuva

Phase 3

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therap…

Relapsed/Refractory Primary Central Nervous System Lymphoma

Estimated

~$10 – $8,750

Ono Pharmaceutical Co., Ltd.NCT07104032

Phase 1

A Phase Ib Trial With Dose Expansion of Epcoritamab in Combination With Ibrutinib in Refractory/Recurrent CNS Lymphoma (EIFEL-Trial)

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects…

Primary Central Nervous System Lymphoma (PCNSL)Primary Central Nervous System LymphomaRelapsed Primary Central Nervous System Lymphoma+4 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07082868

Phase 1

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or…

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more

Estimated

~$10 – $8,750

Curis, Inc.NCT03328078